Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- AOS -8.5% (guidance), ROCK -8.1% (guidance), VALN -0.9% (releases presentation ahead of its Investor Day; Confirmed 2024 Guidance)
Other news:
- TSLA -5.9% (following announcement of Robotaxi named "CyberCab", will be priced under $30,000, will begin production before 2027)
- HUM -3.6% (C.M.S. releases 2025 Medicare Advantage and Part D Star Ratings)
- STLA -3.5% (names Doug Ostermann as CFO; formal process to succeed CEO underway)
- DNLI -3% (informed by its strategic partner Sanofi (SNY) that the K2 Phase 2 study evaluating the safety and efficacy of oditrasertib (SAR443820/DNL788) on serum neurofilament light chain levels in participants with multiple sclerosis was discontinued based on not meeting the primary and key secondary endpoints)
- AORT -2.8% (to present clinical data)
- BP -0.6% (issues Q3 trading statement)